Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gatralimab (GZ402668) in Progressive Multiple Sclerosis
NCT02282826Phase 1Completed
- Sponsor
- Sanofi
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gatralimab in multiple sclerosis (MS) (8 arms), sponsored by Sanofi. Primary endpoint: Treatment Emergent Adverse Events at 4 weeks. Started Oct 2014; status: completed.
02
Drugs
gatralimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02282826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02282826.